Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Moclobemide (Aurorix) in primary major depression

Z Rihmer1, J Barsi, G Vad

  • 1Department of Psychiatry No. XIII, National Institute for Psychiatry and Neurology, Budapest, Hungary.

Progress in Neuro-Psychopharmacology & Biological Psychiatry
|March 1, 1994
PubMed
Summary

Moclobemide (Aurorix), a reversible monoamine-oxidase-A inhibitor, showed effectiveness in treating major depression. This antidepressant was well-tolerated with no serious side effects observed in the study participants.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neural mechanisms for lexical processing in dogs.

Science (New York, N.Y.)·2016
Same author

Recognition of depression and prevention of suicide: the role of general practitioners and general physicians.

International journal of psychiatry in clinical practice·2014
Same author

Cigarette smoking and psychiatric disorders in Hungary.

International journal of psychiatry in clinical practice·2014
Same author

Gender differences in major depressive disorder in a Hungarian community survey.

International journal of psychiatry in clinical practice·2014
Same author

Prevention of depression and suicide by education and medication: impact on male suicidality. An update from the Gotland study.

International journal of psychiatry in clinical practice·2014
Same author

The European Psychiatric Association (EPA) guidance on suicide treatment and prevention.

European psychiatry : the journal of the Association of European Psychiatrists·2011

Area of Science:

  • Pharmacology
  • Psychiatry

Background:

  • Moclobemide (Aurorix) is a novel, reversible inhibitor of monoamine oxidase A (RIMA).
  • It is characterized by short-acting, well-tolerated, and safe antidepressant properties.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of moclobemide in patients with major depression.
  • To investigate the predictive value of pretreatment biological markers on drug response.

Main Methods:

  • An open-label clinical trial was conducted over 6 weeks.
  • Thirty patients diagnosed with major depression (nonpsychotic, nonmelancholic) received oral moclobemide.
  • Pretreatment biological markers including dexamethasone suppression test, platelet-MAO-B activity, 3H-imipramine binding, and thyroid function were assessed.

Related Experiment Videos

Main Results:

  • Out of 25 completers, 14 patients (56%) responded to moclobemide treatment.
  • Eleven patients (44%) were classified as non-responders.
  • The drug was well-tolerated, with no serious adverse events reported.

Conclusions:

  • Moclobemide demonstrates efficacy in treating major depression.
  • Pretreatment biological markers did not predict treatment response to moclobemide.